Drug
Vk2735
Vk2735: highest development phase Phase 3, developed by Viking Therapeutics. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Viking Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| VK2735 NCT07104383 | Phase 3 | Weight Loss |
| VK2735 NCT07868835 | Phase 3 | Weight Loss |
| VK2735 Oral NCT07868939 | Phase 3 | Weight Loss |
| VK2735 NCT07104500 | Phase 3 | Weight Loss |
| VK2735 NCT06828055 | Phase 2 | Weight Loss |
| VK2735 NCT06068946 | Phase 2 | Weight Loss |
| VK2735 NCT05203237 | Phase 1 | Weight Loss |
Latest
No recent events.
Follow Vk2735 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.